Kestrel Therapeutics has filed a notice of an exempt offering of securities to raise $10 Million in New Funding.
According to filings with the U.S. Securities and Exchange Commission, Kestrel Therapeutics is raising up to $10,000,000.00 in new funding. The federal securities law requires the notice to be filed by companies that have sold securities without registration under the Securities Act of 1933 in an offering made under Rule 504 or 506 of Regulation D or Section 4(a)(5) of the Securities Act. A company must file this notice within 15 days after the first sale of securities in the offering. For this purpose, the date of first sale is the date on which the first investor is irrevocably contractually committed to invest. Each issuer of securities that sells its securities in reliance on an exemption provided in Regulation D or Section 4(a)(5) of the Securities Act of 1933 must file this notice containing the information requested with the U.S. Securities and Exchange Commission (SEC) and with the state(s) requiring it. If more than one issuer has sold its securities in the same transaction, all issuers should be identified in this filing with the SEC.
About Kestrel Therapeutics
Exploiting oncogene addiction has been the foundation of extraordinarily fruitful efforts to precisely drug mutated cancer targets and eliminate the malignant cells that carry them. At Kestrel Therapeutics our aspiration is to extend the methodologies and successes of this field to targeting RAS and then to other significant targets. We have created a foundation of unique science that employs a physical understanding of the drug-target interaction, funded by thought-leading investors, to build a lead program designed to potently address all RAS mutations in all tumor types. The prospect of patient benefit through the application of these approaches is profound.
To learn more about Kestrel Therapeutics, visit https://kestreltherapeutics.com/
Kestrel Therapeutics Linkedin Page: https://www.linkedin.com/company/kestreltherapeutics
Contact:
Frank Haluska, President and Chief Executive Officer
617-460-3772
https://www.linkedin.com/in/frank-haluska-03256625/
SOURCE: http://www.intelligence360.io
Copyright (c) 2025 SI360 Inc. All rights reserved.